aceclidine/tropicamide (PRX-100) / LENZ Therap - LARVOL DELTA

Pharmacologic solutions to presbyopia (Cataract & Refractive Surgery Today) - "Pupillary miotics will be the first pharmacologic treatments for presbyopia to market. These agents have demonstrated safety, efficacy, and ease of use in early studies. It remains to be seen which patient populations will be best suited to this form of treatment, and further research is required to demonstrate these agents’ long-term tolerability. Results thus far, however, suggest that pupillary miotics will enable many people to function without wearing glasses. Lens-softening drops also hold promise for the treatment of presbyopia, and the results of a phase 2 trial are currently being evaluated."

Online posting

Stem cell therapy, FDA approvals lead 2019 ophthalmology news (Healio) - "PRX 100 developed by Presbyopia Therapies could be the first pharmaceutical approach for presbyopic near vision correction and may be the first new treatment to go through the FDA for presbyopia correction, according to Richard L. Lindstrom, MD, at Hawaiian Eye 2019."

Media quote

Examining presbyopia treatments: Getting the drop on presbyopia (EyeWorld) - "Presbyopes, in general, represent 'an enormous market, and a very motivated one,' John Hovanesian, MD, said....This is the case with the drops being developed by Allergan (AGN-199201 and AGN-190584), Orasis Pharmaceuticals (CSF-1), and Presbyopia Therapies (PRX-100), Dr. Hovanesian said."

Media quote

Presbyopia-correcting Eye Drops: PRX-100, CSF-1, AGN-199201/AGN-190584, EV06 (AAO 2019) - No abstract available.